We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
-1.04%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$165M
AUM Growth
-$4.08M
(-2.4%)
Cap. Flow
+$2.01M
Cap. Flow
% of AUM
1.22%
Top 10 Holdings %
Top 10 Hldgs %
6.09%
Holding
488
New
53
Increased
73
Reduced
307
Closed
54
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$805K |
| 2 |
Halliburton
HAL
|
+$792K |
| 3 |
Caterpillar
CAT
|
+$787K |
| 4 |
Steel Dynamics
STLD
|
+$775K |
| 5 |
Booking.com
BKNG
|
+$775K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Netflix
NFLX
|
+$1.05M |
| 2 |
Vulcan Materials
VMC
|
+$1.01M |
| 3 |
CoStar Group
CSGP
|
+$998K |
| 4 |
Eli Lilly
LLY
|
+$967K |
| 5 |
Ingersoll Rand
IR
|
+$913K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.63% |
| 2 | Financials | 17.26% |
| 3 | Technology | 14.89% |
| 4 | Energy | 9.42% |
| 5 | Consumer Discretionary | 8.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Revolution Medicines
RVMD
$38.5B
| $108K | 0.07% |
3,916
-390
| -9% | -$11.6K |
|
|
SAGE
327
DELISTED
Sage Therapeutics
SAGE
| $108K | 0.07% |
5,240
-680
| -11% | -$19.6K |
|
328
IDEAYA Biosciences
IDYA
$3.44B
| $107K | 0.07% |
3,977
-401
| -9% | -$10.2K |
|
|
NUVL
329
DELISTED
Nuvalent
NUVL
| $106K | 0.06% |
2,296
-228
| -9% | -$10.1K |
|
330
Biohaven
BHVN
$2.04B
| $106K | 0.06% |
4,057
-403
| -9% | -$8.38K |
|
331
Caribou Biosciences
CRBU
$145M
| $102K | 0.06% |
21,358
-2,128
| -9% | -$13.2K |
|
332
BlackRock 2037 Municipal Target Term Trust
BMN
$157M
| $102K | 0.06% |
+4,479
| New | +$109K |
|
333
PMV Pharmaceuticals
PMVP
$57.6M
| $102K | 0.06% |
16,534
-1,650
| -9% | -$11.3K |
|
334
Ardelyx
ARDX
$1.25B
| $100K | 0.06% |
24,595
-2,454
| -9% | -$9.57K |
|
|
VTYX
335
DELISTED
Ventyx Biosciences
VTYX
| $98.1K | 0.06% |
2,825
-278
| -9% | -$9.61K |
|
|
XIFR
336
XPLR Infrastructure LP
XIFR
$1.07B
| $97.3K | 0.06% |
3,275
-431
| -12% | -$21.8K |
|
337
Vaxcyte
PCVX
$7.65B
| $96K | 0.06% |
1,883
-192
| -9% | -$9.47K |
|
338
Immatics
IMTX
$1.2B
| $95.7K | 0.06% |
8,263
-825
| -9% | -$9.85K |
|
339
AnaptysBio
ANAB
$1.53B
| $95.6K | 0.06% |
5,323
-536
| -9% | -$10.2K |
|
340
Summit Therapeutics
SMMT
$9.88B
| $94.8K | 0.06% |
50,714
-5,049
| -9% | -$9.63K |
|
341
Disc Medicine
IRON
$2.8B
| $94.6K | 0.06% |
2,014
-205
| -9% | -$10.3K |
|
|
ACLX
342
DELISTED
Arcellx
ACLX
| $93.5K | 0.06% |
2,605
-261
| -9% | -$9K |
|
|
CMPS
343
Compass Pathways
CMPS
$1.48B
| $92.9K | 0.06% |
12,549
-1,250
| -9% | -$11.1K |
|
344
Novavax
NVAX
$1.21B
| $92.8K | 0.06% |
12,813
-1,272
| -9% | -$10.2K |
|
345
Arcturus Therapeutics
ARCT
$161M
| $91.5K | 0.06% |
3,582
-354
| -9% | -$10.9K |
|
|
AKRO
346
DELISTED
Akero Therapeutics
AKRO
| $90.8K | 0.06% |
1,795
-176
| -9% | -$8.2K |
|
347
Arcus Biosciences
RCUS
$3.31B
| $90.5K | 0.06% |
5,042
-506
| -9% | -$10.2K |
|
|
DAWN
348
DELISTED
Day One Biopharmaceuticals
DAWN
| $90K | 0.05% |
7,339
-734
| -9% | -$9.57K |
|
349
Rocket Pharmaceuticals
RCKT
$336M
| $89.3K | 0.05% |
4,356
-436
| -9% | -$7.92K |
|
350
Krystal Biotech
KRYS
$10.7B
| $88.9K | 0.05% |
766
-74
| -9% | -$9.03K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
RC
Virtus ETF Advisers's Q3 2023 Portfolio in Review
As of Q3 2023, Virtus ETF Advisers held 488 positions worth $165M, down 2.4% from $169M the previous quarter. Its ten largest holdings account for 6.1% of the portfolio.
Virtus ETF Advisers's Q3 2023 filing shows 53 new, 73 increased, 307 reduced and 54 closed positions. Its largest new stake was Alphabet (Google) Class A: 6,222 shares worth $814K. The largest sale was Netflix, an estimated $1.05M.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, down from 28% a quarter earlier, followed by Financials and Technology.
- Virtus ETF Advisers's largest Q3 2023 buy was Alphabet (Google) Class A: 6,222 shares worth $814K.
- Virtus ETF Advisers added most to Coterra Energy in Q3 2023, an estimated $732K increase.
- Virtus ETF Advisers's biggest Q3 2023 reduction was Incyte, cutting an estimated $701K.
- Virtus ETF Advisers fully exited Netflix in Q3 2023, selling an estimated $1.05M.
- Virtus ETF Advisers's ten largest holdings make up 6.1% of its $165M portfolio in Q3 2023.
- Virtus ETF Advisers opened 53 new positions and closed 54 in Q3 2023.
- Virtus ETF Advisers's portfolio value fell 2.4% quarter-over-quarter to $165M.
Based on Virtus ETF Advisers's 13F filing for Q3 2023, filed 7 Nov 2023.